AR058670A1 - Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas - Google Patents

Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas

Info

Publication number
AR058670A1
AR058670A1 ARP060104077A ARP060104077A AR058670A1 AR 058670 A1 AR058670 A1 AR 058670A1 AR P060104077 A ARP060104077 A AR P060104077A AR P060104077 A ARP060104077 A AR P060104077A AR 058670 A1 AR058670 A1 AR 058670A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
ciclopropil
aminas
modulators
methanone
Prior art date
Application number
ARP060104077A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR058670A1 publication Critical patent/AR058670A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composiciones farmacéuticas que los contienen y uso de los mismos en el tratamieno de enfermedades mediadas por el receptor H3 de histamina. Reivindicacion 1: Un compuesto seleccionado del grupo integrado por: (4-ciclopropilpiperazin-1-il)-(4- morfolin-4-ilmetil-fenil)-metanona, (4-ciclopropil-piperazin-1-il)-[4-(4-fluor-piperidin-1-ilmetil)-fenil]-metanona, (4-ciclopropil-piperazin-1-il)-(4-tiomorfolin-4-ilmetil-fenil)-metanona, y (4-ciclopropil-piperazin-1-il)-[4-(2-hidroximetil- morfolin-4-ilmetil)-fenil]-metanona, y enantiomeros, hidratos, solvatos, y sales farmacéuticas aceptables de las mismas.
ARP060104077A 2005-09-16 2006-09-18 Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas AR058670A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71765905P 2005-09-16 2005-09-16
US11/531,849 US7687499B2 (en) 2005-09-16 2006-09-14 Cyclopropyl amines as modulators of the histamine H3 receptor

Publications (1)

Publication Number Publication Date
AR058670A1 true AR058670A1 (es) 2008-02-20

Family

ID=37889336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104077A AR058670A1 (es) 2005-09-16 2006-09-18 Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas

Country Status (33)

Country Link
US (3) US7687499B2 (es)
EP (1) EP1948607B1 (es)
JP (1) JP5185120B2 (es)
KR (1) KR101336106B1 (es)
CN (1) CN101321730B (es)
AR (1) AR058670A1 (es)
AT (1) ATE463481T1 (es)
AU (1) AU2006292598B2 (es)
BR (1) BRPI0622428A2 (es)
CA (1) CA2622760C (es)
CR (1) CR9891A (es)
CY (1) CY1110167T1 (es)
DE (1) DE602006013501D1 (es)
DK (1) DK1948607T3 (es)
EA (1) EA014370B1 (es)
EC (1) ECSP088279A (es)
ES (1) ES2342323T3 (es)
HK (1) HK1123291A1 (es)
HR (1) HRP20100263T1 (es)
IL (1) IL190110A (es)
ME (1) ME01181B (es)
MX (1) MX2008003691A (es)
MY (1) MY145305A (es)
NO (1) NO340949B1 (es)
NZ (1) NZ566533A (es)
PL (1) PL1948607T3 (es)
PT (1) PT1948607E (es)
RS (1) RS51311B (es)
SI (1) SI1948607T1 (es)
TW (1) TWI418552B (es)
UA (1) UA96424C2 (es)
WO (1) WO2007035425A2 (es)
ZA (1) ZA200803337B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761496A2 (en) * 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
JP5185120B2 (ja) 2005-09-16 2013-04-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのシクロプロピルアミン
KR20080067362A (ko) * 2005-10-31 2008-07-18 얀센 파마슈티카 엔.브이. 사이클로프로필-아미드 유도체의 제조 방법
US7795426B2 (en) * 2005-10-31 2010-09-14 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
EA015555B1 (ru) * 2006-05-30 2011-08-30 Янссен Фармацевтика Н.В. Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ611323A (en) * 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
CN101511807A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 组胺h3受体的取代的苯甲酰胺调节剂
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
CA2880932A1 (en) * 2006-12-14 2008-06-26 Janssen Pharmaceutica N.V. Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
DK2195293T3 (da) 2007-08-22 2014-02-03 Astrazeneca Ab Cyclopropylamidderivater
CA2706328C (en) * 2007-11-20 2016-04-19 Janssen Pharmaceutica N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
SG10201501226VA (en) * 2010-02-18 2015-04-29 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
BR112012020780A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab forma sólida, composição farmacêutica, e, uso de uma forma sólida.
PL3789038T3 (pl) 2010-05-14 2023-01-23 The Board Of Trustees Of The Leland Stanford Junior University Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US20130339859A1 (en) 2012-06-15 2013-12-19 Muzik LLC Interactive networked headphones
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2017534132A (ja) 2014-10-10 2017-11-16 ミュージック エルエルシー ユーザー相互作用を共有するための装置
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
US3886160A (en) 1972-09-28 1975-05-27 Searle & Co 2-(2-Methyl-5-nitro-1-imidazolyl) ethyl-2-thiopseudoureas
FR2543139B1 (fr) * 1983-03-22 1985-08-16 Cerm Cent Europ Rech Mauvernay Derives de (1-alcoxy 2-amino) ethyl pyridine ou pyrazine, leur preparation et leur application en therapeutique
JPH0641455B2 (ja) 1984-12-10 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JP2813747B2 (ja) 1989-05-22 1998-10-22 富士写真フイルム株式会社 画像形成法
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
JPH10511356A (ja) 1994-12-22 1998-11-04 スミスクライン・ビーチャム・コーポレイション フィブリノゲン受容体拮抗物質
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1059954A (ja) 1996-08-14 1998-03-03 Takeda Chem Ind Ltd 環状アミン誘導体およびそれを含んでなる医薬
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
CN1278269A (zh) 1997-11-07 2000-12-27 第一制药株式会社 哌嗪-环糊精复合体
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0978512A1 (en) 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
DE60126785T2 (de) 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
HU230055B1 (hu) 2000-08-08 2015-06-29 Ortho-Mcneil Pharmaceutical Inc. Nem-imidazol ariloxi-alkil-aminok
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
JP2004510712A (ja) 2000-09-22 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド オクタヒドロ−インドリジンおよびキノリジンおよびヘキサヒドロ−ピロリジン
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2003000314A2 (en) 2001-06-20 2003-01-03 The Regents Of The University Of California Hemodialysis system and method
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
ATE450508T1 (de) 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003050099A1 (en) 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
ES2292931T3 (es) 2002-02-01 2008-03-16 Novo Nordisk A/S Amidas de azetidinas, pirrolidinas, piperidinas y azepanos aminoalquilo sustituidos.
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
BRPI0315644B8 (pt) 2002-10-23 2021-05-25 Janssen Pharmaceutica Nv compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CA2589748C (en) 2004-12-24 2013-08-13 Astrazeneca Ab Heterocyclic compounds as ccr2b antagonists
JP5185120B2 (ja) 2005-09-16 2013-04-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのシクロプロピルアミン
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives

Also Published As

Publication number Publication date
JP2009508864A (ja) 2009-03-05
ES2342323T3 (es) 2010-07-05
ECSP088279A (es) 2008-04-28
HK1123291A1 (en) 2009-06-12
ZA200803337B (en) 2009-10-28
CY1110167T1 (el) 2015-01-14
MY145305A (en) 2012-01-13
EA014370B1 (ru) 2010-10-29
TW200804337A (en) 2008-01-16
US8026242B2 (en) 2011-09-27
ATE463481T1 (de) 2010-04-15
US20100130485A1 (en) 2010-05-27
HRP20100263T1 (hr) 2010-06-30
NO340949B1 (no) 2017-07-24
IL190110A (en) 2014-01-30
KR20080056198A (ko) 2008-06-20
MX2008003691A (es) 2009-02-27
SI1948607T1 (sl) 2010-07-30
US20110136797A1 (en) 2011-06-09
IL190110A0 (en) 2008-12-29
PT1948607E (pt) 2010-06-02
NO20081788L (no) 2008-05-29
BRPI0622428A2 (pt) 2021-05-11
UA96424C2 (ru) 2011-11-10
US20070066821A1 (en) 2007-03-22
WO2007035425A2 (en) 2007-03-29
CA2622760C (en) 2012-12-04
AU2006292598B2 (en) 2012-06-21
CN101321730A (zh) 2008-12-10
NZ566533A (en) 2010-11-26
CN101321730B (zh) 2012-11-14
US7910582B2 (en) 2011-03-22
TWI418552B (zh) 2013-12-11
RS51311B (sr) 2010-12-31
WO2007035425A3 (en) 2008-07-24
AU2006292598A1 (en) 2007-03-29
CR9891A (es) 2009-01-16
ME01181B (me) 2013-03-20
PL1948607T3 (pl) 2010-09-30
KR101336106B1 (ko) 2013-12-05
DE602006013501D1 (de) 2010-05-20
DK1948607T3 (da) 2010-07-26
JP5185120B2 (ja) 2013-04-17
EA200800835A1 (ru) 2008-12-30
CA2622760A1 (en) 2007-03-29
EP1948607B1 (en) 2010-04-07
US7687499B2 (en) 2010-03-30
EP1948607A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
AR058670A1 (es) Ciclopropil aminas como moduladores del receptor h3 de histamina. composiciones farmaceuticas
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
PA8631301A1 (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
PH12016501440A1 (en) Novel heterocyclic compounds
ATE504565T1 (de) Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CR11819A (es) Compuestos de isoindolina 5-sustituidos
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
AR058807A1 (es) 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
BRPI0612888B8 (pt) anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
CR11036A (es) Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos
UY28692A1 (es) Nuevos derivados de quinolina
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
UY30835A1 (es) 8-alquinilxantinas y derivados
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico

Legal Events

Date Code Title Description
FB Suspension of granting procedure